Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15961772 | 0.87 | ERCC1 (0.55) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| Phenylacetic Acid SCHEMBL27608313 | 0.84 | LMNA (0.56) | LMNAFFAR1FFAR4AKR1B1MEP1A | |
| SCHEMBL6714339 | 0.84 | MAPK8 (0.56) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL30860058 | 0.84 | ERCC1 (0.52) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL3018613 | 0.84 | ERCC1 (0.52) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL30489963 | 0.84 | MAPK8 (0.56) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL6714330 | 0.84 | ERCC1 (0.52) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL200244 | 0.84 | ERCC1 (0.52) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL4558717 | 0.84 | ERCC1 (0.52) | LMNAFFAR1FFAR4ERCC1ERCC4 | |
| SCHEMBL20272613 | 0.83 | LMNA (0.51) | LMNAFFAR1FFAR4ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-1206446-A1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | Boehringer Ingelheim Pharma KG (DE) | 2002-05-22 | — | — | EP | disclosed |
| EP-1091955-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001010823-A1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-02-15 | — | — | WO | disclosed |
| WO-1999050263-A1 | QUINOLONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5504244-A | 3-(4-N-PENTYLPHENYLACYL)BENZOIC ACID OR SALT OR ESTER | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1995002579-A1 | SUBSTITUTED AZETIDINONE AMIDE DERIVATIVES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | ZENECA LIMITED (GB) | 1995-01-26 | — | — | WO | disclosed |
| EP-0224751-B1 | DIPHOSPHONIC-ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1990-01-24 | — | — | EP | disclosed |
| US-4719203-A | CALCIUM METABOLISM DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1988-01-12 | — | — | US | disclosed |
| EP-0224751-A1 | Diphosphonic-acid derivatives, process for preparing them and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | LMNA 581/4885FFAR1 1414/4885FFAR4 2141/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | LMNA 1266/4885FFAR1 1045/4885FFAR4 1210/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | LMNA 1620/4885FFAR1 3199/4885FFAR4 3401/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | LMNA 1266/4885FFAR1 1045/4885FFAR4 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.